Ikuko Matsumura1, Hiroaki Shimizu1, Hiromasa Iino2, Chiaki Naito3, Yuri Miyazawa4, Takuma Ishizaki1, Kohtaro Toyama2, Hiromi Koiso1, Akihiko Yokohama1, Morio Matsumoto4, Hidemi Ogura3, Norifumi Tsukamoto1, Junko Hirato5, Hiroshi Handa1 (1.Hematology, Gunma University Hospital, Gunma, Japan, 2.Hematology, Fujioka General Hospital, Gunma, Japan, 3.Hematology, Maebashi Red Cross Hospital, Gunma, Japan, 4.Hematology, Shibukawa Medical Centor, Gunma, Japan, 5.Pathology, Gunma University Hospital, Gunma, Japan)
Session information
Oral Session
Oral Session 2-8C DLBCL: Treatment
Sat. Oct 13, 2018 2:50 PM - 3:50 PM No.8 (Osaka International Convention Center, 10F 1002)
Chair: Kana Miyazaki (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan)
Kana Miyazaki1, Naoko Asano2, Tomomi Yamada3, Kohta Miyawaki4, Hirotaka Takasaki5, Tadahiko Igarashi6, Momoko Nishikori7, Kinya Ohata8, Kazutaka Sunami9, Isao Yoshida10, Go Yamamoto11, Naoki Takahashi12, Masataka Okamoto13, Hiroki Yano14, Yuki Nishimura15, Satoshi Tamaru15, Masakatsu Nishikawa15, Koji Izutsu11,16, Tomohiro Kinoshita17, Junji Suzumiya18, Koichi Ohshima19, Koji Kato4, Naoyuki Katayama1, Motoko Yamaguchi1 (1.Department of Hematology and Oncology, Mie University, Tsu, Japan, 2.Nagano Prefectural Shinshu Medical Center, Suzaka, Japan, 3.Osaka University Hospital, Suita, Japan, 4.Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 5.Kanagawa Cancer Center, Yokohama, Japan, 6.Gunma Cancer Center, Ohta, Japan, 7.Kyoto University, Kyoto, Japan, 8.Kanazawa University, Kanazawa, Japan, 9.Okayama Medical Center, Okayama, Japan, 10.Shikoku Cancer Center, Matsuyama, Japan, 11.Toranomon Hospital, Tokyo, Japan, 12.International Medical Center, Saitama Medical University, Hidaka, Japan, 13.Fujita Health University, Toyoake, Japan, 14.Kainan Hospital, Yatomi, Japan, 15.Mie University Hospital, Tsu, Japan, 16.National Cancer Center Hospital, Tokyo, Japan, 17.Aichi Cancer Center Hospital, Nagoya, Japan, 18.Shimane University Hospital, Izumo, Japan, 19.Kurume University, Kurume, Japan)
Shinichiro Matsuda1, Youko Suehiro2, Naoto Tomita3, Koji Izutsu4, Noriko Fukuhara5, Yoshitaka Imaizumi6, Kazuyuki Shimada7, Tomonori Nakazato8, Isao Yoshida9, Tsutomu Takahashi1, Ritsuro Suzuki1, Motoko Yamaguchi10, Junji Suzumiya1 (1.Oncology/Hematology, Shimane University Hospital, Shimane, Japan, 2.Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 3.St. Marianna University School of Medicine, Kanagawa, Japan, 4.Hematology, Toranomon Hospital, Tokyo, Japan, 5.Hematology, Tohoku University Hospital, Miyagi, Japan, 6.Hematology, Nagasaki University Hospital, Nagasaki, Japan, 7.Hematology, Nagoya University Hospital, Aichi, Japan, 8.Hematology, Yokohama Municipal Citizens Hospital, Kanagawa, Japan, 9.Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan, 10.Hematology and Oncology, Mie University Hospital, Mie, Japan)
Dai Maruyama1, Yoshitoyo Kagami2, Taro Shibata3, Kensei Tobinai1, Kazuhito Yamamoto4, Yoshitaka Imaizumi5, Toshiki Uchida6, Kazuyuki Shimada7, Koichiro Minauchi8, Noriko Fukuhara9, Hirofumi Kobayashi10, Nobuhiko Yamauchi11, Hideki Tsujimura12, Akira Hangaishi13, Ryo Tominaga14, Youko Suehiro15, Shinichiro Yoshida16, Yoshiko Inoue17, Sachiko Suzuki18, Michihide Tokuhira19, Shigeru Kusumoto20, Junya Kuroda21, Yoshihiro Yakushijin22, Yasushi Takamatsu23, Yasushi Kubota24, Kisato Nosaka25, Satoko Morishima26, Shigeo Nakamura27, Tomomitsu Hotta28, Yasuo Morishima4, Kunihiro Tsukasaki11, Hirokazu Nagai29 (1.Hematology., National Cancer Center Hospital, Tokyo, Japan, 2.Hematology, Toyota Kosei Hospital, Toyota, Japan, 3.JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan, 4.Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan, 5.Hematology, Nagasaki University Hospital, Nagasaki, Japan, 6.Hematology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan, 7.Hematology, Nagoya University Hospital, Nagoya, Japan, 8.Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan, 9.Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 10.Hematology, Saitama Cancer Center Hospital, Saitama, Japan, 11.Hematology, National Cancer Center East, Kashiwa, Japan, 12.Hematology-Oncology, Chiba Cancer Center, Chiba, Japan, 13.Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 14.Hematology, Hyogo Cancer Center, Akashi, Japan, 15.Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 16.Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan, 17.Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan, 18.Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan, 19.Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 20.Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan, 21.Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan, 22.First Department of Internal Medicine, Ehime University Hospital, Toon, Japan, 23.Medical Oncology, Hematology and Infectious Diseases, Fukuoka University, Fukuoka, Japan, 24.Hematology, Respiratory Medicine and Oncology, Saga University, Saga, Japan, 25.Hematology, Kumamoto University School of Medicine, Kumamoto, Japan, 26.Second Department of Internal Medicine, Ryukyu University, Okinawa, Japan, 27.Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan, 28.National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 29.Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan)
Futoshi Iioka, Yusuke Toda, Wataru Maruyama, Takashi Akasaka, Hitoshi Ohno (Department of Hematology, Tenri Hospital)
Kazuki Taoka1, Ayako Karakawa2, Kumi Nakazaki1, Kazuhiro Toyama1, Shunya Arai1, Rie Tanaka2, Toshikatu Kaburaki2, Makoto Aihara2, Mineo Kurokawa1 (1.Hematology and Oncology, The University of Tokyo, Tokyo, Japan, 2.Department of Ophthalmology, The University of Tokyo Hospital, Tokyo, Japan.)